Exploring factors that affect weight loss outcomes after treatment for obesity
Exploration of Effect Weight Loss Outcome Related to Factors After Treatment of Weight Loss (WRRFA).
This study looks at the different reasons why people might regain weight after obesity treatments like surgery or medications to help improve support for those struggling with weight loss.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 900 (estimated) |
| Ages | 20 Years to 65 Years |
| Sex | All |
| Sponsor | E-DA Hospital Academic / other |
| Locations | 1 site (Kaohsiung, Yanchao District) |
| Trial ID | NCT06482411 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the complex risk factors that contribute to weight regain after various obesity treatments, including bariatric surgery and anti-obesity medications. It utilizes a range of questionnaires to assess demographic information, dietary habits, quality of life, psychological status, and food addiction among participants. The goal is to identify the underlying reasons for weight loss failure, which can inform future interventions and support for patients struggling with obesity. Participants will be evaluated based on their responses to these assessments to better understand the multifaceted nature of weight management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 20 to 65 with a BMI of 30 or higher who have previously attempted exercise or dietary control.
Not a fit: Patients who have undergone bariatric surgery or have severe psychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the factors influencing weight regain, leading to improved treatment strategies for obesity.
How similar studies have performed: While there have been studies exploring weight loss outcomes, this particular approach focusing on a comprehensive assessment of multiple risk factors is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion 1.65 ≥ Age ≥ 20 years-old. 2.BMI ≥ 30. 3.Once attempted exercise or dietary control. 4.No cognitive deficiency and clear communication. 5. No severe psychotic disorders were evaluated by the psychiatrist. (e.g. schizophrenia, bipolar disorder, or severe depression). 6. Signing the informed consent form for clinical trials. Exclusion 1. Once underwent bariatric surgery. 2. Once used the GLP-1 receptor agonist. 3. Pregnancy or preparation for pregnancy. 4. Once and presenting gastric cancer. 5. Presenting the other cancer. 6. The abnormal endocrine system causes diseases with obesity. 7. Major organ abnormalities (e.g., kidney failure, liver failure, heart failure, etc.). 8. Gastric ulcer, and severe gastroesophageal reflux. 9. Severe psychiatric disorders (schizophrenia, severe bipolar disorder, and depression, etc.). 10. Bulimia nervosa or anorexia nervosa. 11. Drug and alcohol abuse. 12. Helicobacter pylori is not for bariatric surgery. 13. The following diseases or conditions preclude the use of Contrave: 1)Uncontrolled hypertension, 2) History or current diagnosis of epilepsy, 3) Allergy to this medication, 4) Medications evaluated by a physician to interact with this drug (antidepressants, antipsychotics, liver medications, heart medications). 14. The following diseases or conditions preclude the use of GLP-1 medication: 1) History or current diagnosis of medullary thyroid carcinoma, 2)History or current diagnosis of Multiple Endocrine Neoplasia syndrome type 2, 3)Allergy to this medication, 4)Medications evaluated by a physician to interact with this drug (antidepressants, antipsychotics, liver medications, heart medications). 15. The following diseases or conditions preclude the use of Xenical medication: 1) History or current diagnosis of cholestasis, 2) Allergy to this medication, 3) Medications evaluated by a physician to interact with this drug (antidepressants, antipsychotics, liver medications, heart medications).
Where this trial is running
Kaohsiung, Yanchao District
- Chung-Yen Chen — Kaohsiung, Yanchao District, Taiwan (Recruiting)
Study contacts
- Study coordinator: Chung-Yen Chen, MD.
- Email: drchenchungyen@gmail.com
- Phone: 886-9-75106259
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.